Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ACRS
stocks logo

ACRS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.14M
-76.71%
-0.133
-86.88%
2.30M
+58.08%
-0.150
+25%
2.33M
+30.84%
-0.140
+7.69%
Estimates Revision
The market is revising Upward the revenue expectations for Aclaris Therapeutics, Inc. (ACRS) for FY2025, with the revenue forecasts being adjusted by 56.44% over the past three months. During the same period, the stock price has changed by 43.33%.
Revenue Estimates for FY2025
Revise Upward
up Image
+56.44%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-14.52%
In Past 3 Month
Stock Price
Go Up
up Image
+43.33%
In Past 3 Month
Wall Street analysts forecast ACRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRS is 9.25 USD with a low forecast of 6.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast ACRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRS is 9.25 USD with a low forecast of 6.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.010
sliders
Low
6.00
Averages
9.25
High
16.00
Current: 3.010
sliders
Low
6.00
Averages
9.25
High
16.00
Piper Sandler
Biren Amin
Overweight
initiated
$6
2025-07-09
Reason
Piper Sandler
Biren Amin
Price Target
$6
2025-07-09
initiated
Overweight
Reason
Piper Sandler analyst Biren Amin assumed coverage of Aclaris Therapeutics with an Overweight rating and $6 price target. The shares are currently trading below the company's cash position with three data readouts over the next 12-15 months, the analyst tells investors in a research note. The firm believes each readout offers "meaningful upside" to Aclaris shares. Piper believes the company's lead program, bosakitug, has demonstrated proof of efficacy activity in a small Phase 2a study in moderate to severe atopic dermatitis.
Wedbush
NULL -> Outperform
initiated
$8
2025-05-28
Reason
Wedbush
Price Target
$8
2025-05-28
initiated
NULL -> Outperform
Reason
Wedbush initiated coverage of Aclaris Therapeutics with an Outperform rating and $8 price target.
Wedbush
Outperform
initiated
$8
2025-05-28
Reason
Wedbush
Price Target
$8
2025-05-28
initiated
Outperform
Reason
H.C. Wainwright
Raghuram Selvaraju
Buy
downgrade
$20 -> $16
2025-05-14
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$20 -> $16
2025-05-14
downgrade
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Aclaris Therapeutics to $16 from $20 and keeps a Buy rating on the shares following the Q1 report.
Scotiabank
Louise Chen
Outperform
downgrade
$15 -> $9
2025-05-09
Reason
Scotiabank
Louise Chen
Price Target
$15 -> $9
2025-05-09
downgrade
Outperform
Reason
Scotiabank analyst Louise Chen lowered the firm's price target on Aclaris Therapeutics to $9 from $15 and keeps an Outperform rating on the shares. The firm is lowering its price target on the stock due to lower sales for bosakitug, the analyst tells investors. The firm, however, continues to believe pipeline advancements and commercialization, as well as potential partnerships, will drive upwards earnings revisions.
Cantor Fitzgerald
Prakhar Agrawal
Buy
Reiterates
n/a
2025-03-18
Reason
Cantor Fitzgerald
Prakhar Agrawal
Price Target
n/a
2025-03-18
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Aclaris Therapeutics Inc (ACRS.O) is -5.45, compared to its 5-year average forward P/E of -6.54. For a more detailed relative valuation and DCF analysis to assess Aclaris Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.54
Current PE
-5.45
Overvalued PE
-2.04
Undervalued PE
-11.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.70
Undervalued EV/EBITDA
-3.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
72.31
Current PS
0.00
Overvalued PS
134.60
Undervalued PS
10.01
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ACRS News & Events

Events Timeline

(ET)
2025-11-06
07:25:51
Aclaris Therapeutics announces Q3 earnings per share of 12 cents, below consensus estimate of 14 cents.
select
2025-08-07 (ET)
2025-08-07
07:29:32
Aclaris Therapeutics reports Q2 EPS (13c), consensus (13c)
select
2025-07-29 (ET)
2025-07-29
16:57:47
Aclaris announces ATI-2138 trial meets primary, secondary endpoints
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
10-21NASDAQ.COM
Reasons to Consider Aclaris Therapeutics (ACRS) as a Strong Momentum Stock: Is It Time to Buy?

  • Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation that they will continue to rise. The Zacks Momentum Style Score helps identify stocks with strong momentum characteristics.

  • Aclaris Therapeutics Performance: Aclaris Therapeutics (ACRS) has a Momentum Style Score of B and a Zacks Rank of #2 (Buy), with shares increasing 19.64% over the past quarter and 66.12% over the past year, outperforming the S&P 500.

  • Volume and Estimate Revisions: ACRS has an average 20-day trading volume of 1,004,293 shares, indicating bullish momentum. Additionally, recent earnings estimate revisions have been positive, contributing to its favorable consensus estimate.

  • Investment Recommendations: The article suggests Aclaris Therapeutics as a promising stock pick for investors looking for momentum opportunities, alongside other stocks identified by Zacks Investment Research that are expected to perform well in the near term.

[object Object]
Preview
4.0
10-20Benzinga
HC Wainwright & Co. Affirms Buy Rating for Aclaris Therapeutics, Keeps $16 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.

  • Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

[object Object]
Preview
5.0
09-21Yahoo Finance
Acadian Boosts Investment in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Results Come to Forefront

  • Investment Activity: Acadian Asset Management LLC increased its stake in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) by 25.9%, acquiring 451,044 shares, which brings their total ownership to 2,195,191 shares.

  • Clinical Development: Aclaris is advancing its drug ATI-2138 for atopic dermatitis, with new Phase 2a trial data set to be presented at the 2025 EADV Congress, indicating potential for future success despite the company's past challenges.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aclaris Therapeutics Inc (ACRS) stock price today?

The current price of ACRS is 3.01 USD — it has increased 8.27 % in the last trading day.

arrow icon

What is Aclaris Therapeutics Inc (ACRS)'s business?

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).

arrow icon

What is the price predicton of ACRS Stock?

Wall Street analysts forecast ACRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRS is 9.25 USD with a low forecast of 6.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aclaris Therapeutics Inc (ACRS)'s revenue for the last quarter?

Aclaris Therapeutics Inc revenue for the last quarter amounts to 3.30M USD, decreased -24.09 % YoY.

arrow icon

What is Aclaris Therapeutics Inc (ACRS)'s earnings per share (EPS) for the last quarter?

Aclaris Therapeutics Inc. EPS for the last quarter amounts to -0.12 USD, increased 9.09 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aclaris Therapeutics Inc (ACRS)'s fundamentals?

The market is revising Upward the revenue expectations for Aclaris Therapeutics, Inc. (ACRS) for FY2025, with the revenue forecasts being adjusted by 56.44% over the past three months. During the same period, the stock price has changed by 43.33%.
arrow icon

How many employees does Aclaris Therapeutics Inc (ACRS). have?

Aclaris Therapeutics Inc (ACRS) has 64 emplpoyees as of December 05 2025.

arrow icon

What is Aclaris Therapeutics Inc (ACRS) market cap?

Today ACRS has the market capitalization of 326.12M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free